Opana Sales Calls Didn't Cause Rx Rise, Economist Testifies

Law360 (July 20, 2021, 9:00 PM EDT) -- An economist testifying for Endo in a California opioid trial said Tuesday that a data set of 250,000 sales calls related to the opioid Opana ER showed no overall effect on prescribing.

Justin McCrary, an economist who is also a professor at Columbia Law School, appeared as an expert witness to argue that Endo did not help fuel a public nuisance in three California counties and one city.

McCrary, who specializes in analyzing large datasets, said he looked at a set of 250,000 Opana ER sales calls, or details, and compared them to prescriptions written.

"The people's theory seems to be...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!